A novel combination of an investigational intravesical drug delivery system designed to provide sustained release of gemcitabine into the bladder (Gem-iDRS, Inlexzo) and systemic treatment with the ...

As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...

For most people, a headache or a twinge in the side is just a passing concern. However, 4% of the population sees in these discomforts the omen of a grim fate, the beginning of a certain illness. "You ...

ImmunityBio Inc. (NASDAQ:IBRX) is one of the most buzzing stocks to buy with the highest upside potential. On March 9, ...

The phase 2, single-arm INDIBLADE trial assessed induction ipilimumab plus nivolumab followed by CRT in patients with MIBC.

Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting ...

For Grant Nerren, 2025 was a busy year, full of highs and lows that likely contributed to a certain level of stress. Life was ...

Large international study finds nearly half of patients admitted with visible blood in urine receive no imaging, delaying ...

Johnson & Johnson JNJ reported positive results from an early-stage study evaluating its investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with ...

Erda-iDRS delivers erdafitinib into the bladder over three months, enabling localised therapy and reducing systemic exposure.

One in ten emergency patients with visible blood in their urine die within three months of presenting at A&E, new research has found.

Bladder cancer is often discovered because a person notices blood in their urine. For many patients, this is the first warning sign that something is wrong. Seeing this change usually encourages ...